FDA has accepted the supplemental biologics license application for use of interleukin-23 inhibitor tildrakizumab (Ilumy

FDA has accepted the supplemental biologics license application for use of interleukin-23 inhibitor tildrakizumab (Ilumya; Sun Pharma) in active psoriatic arthritis (PsA) in adults. https://t.co/cwqz9DoWsL https://t.co/ut0A4MwqW7

Links:

Tildrakizumab Now Under FDA Review for Psoriatic Arthritis Indication https://buff.ly/O91H0Yd